Comparison of renal protective effects of atorvastatin and rosuvastatin – results of PLANET I and PLANET II trials Review article
Article Sidebar
Published:
Dec 31, 2010
Keywords:
chronic kidney disease, statins, trial results, PLANET I, PLANET II
Main Article Content
Abstract
Chronic kidney disease patients are highly prone to cardiovascular disease. Lipid balance disturbances are one of the most common causes of cardiovascular complications and the clinical studies with statins have produced mixed results in this group of patients. In article, we present the preliminary results of two randomized multinational PLANET trials tested the effects of atorvastatin 80 mg/day or rosuvastatin 10 or 40 mg/day on urinary protein excretion and renal function in hypercholesterolemic patients with moderate proteinuria.
Article Details
How to Cite
Rawdanowicz , J., Hrynkiewicz-Szymańska, A., & Rostek, M. (2010). Comparison of renal protective effects of atorvastatin and rosuvastatin – results of PLANET I and PLANET II trials. Medycyna Faktow (J EBM), 3(4(9), 8-11. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2558
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Coresh J., Selvin E., Stevens L.A. et al.: Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047.
2. Coresh J., Astor B.C., Greene T. et al.: Prevalence of chronic kidney disease and decreased kidney function in the adults US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 2003; 41: 1-12.
3. Król E., Rutkowski B.: Przewlekła choroba nerek – klasyfikacja, epidemiologia i diagnostyka. Forum Nefrologiczne 2008; 1: 1-6.
4. Puka J., Rutkowski B., Lichodziejewska-Niemierko M. et al.: Raport o stanie leczenia nerkozastępczego w Polsce 2003. Akademia Medyczna, Gdańsk 2004.
5. Hillege H.L., Fidler V., Dierecks G.F. et al.: Urinary albumin predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
6. Hillege H.L., Janssen W.M., Bak A.A. et al.: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular morbidity. J. Intern. Med. 2001; 249: 519-526.
7. Bigazzi R., Bianchi S., Nenci R. et al.: Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J. Hum. Hypertens. 1995; 9: 827-833.
8. Keane W.F.: Lipids and progressive renal failure. Wien Klin. Wochenschr. 1996; 108 (14): 420-424.
9. Oda H., Keane W.F.: Recent advances in statins and the kidney. Kidney Int. Suppl. 1999 Jul; 71: S2-5.
10. de Zeeuw D.: Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Renal Association-European Dialysis and Transplant Association Congress; June 27, 2010; Munich,
Germany.
2. Coresh J., Astor B.C., Greene T. et al.: Prevalence of chronic kidney disease and decreased kidney function in the adults US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 2003; 41: 1-12.
3. Król E., Rutkowski B.: Przewlekła choroba nerek – klasyfikacja, epidemiologia i diagnostyka. Forum Nefrologiczne 2008; 1: 1-6.
4. Puka J., Rutkowski B., Lichodziejewska-Niemierko M. et al.: Raport o stanie leczenia nerkozastępczego w Polsce 2003. Akademia Medyczna, Gdańsk 2004.
5. Hillege H.L., Fidler V., Dierecks G.F. et al.: Urinary albumin predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
6. Hillege H.L., Janssen W.M., Bak A.A. et al.: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular morbidity. J. Intern. Med. 2001; 249: 519-526.
7. Bigazzi R., Bianchi S., Nenci R. et al.: Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J. Hum. Hypertens. 1995; 9: 827-833.
8. Keane W.F.: Lipids and progressive renal failure. Wien Klin. Wochenschr. 1996; 108 (14): 420-424.
9. Oda H., Keane W.F.: Recent advances in statins and the kidney. Kidney Int. Suppl. 1999 Jul; 71: S2-5.
10. de Zeeuw D.: Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Renal Association-European Dialysis and Transplant Association Congress; June 27, 2010; Munich,
Germany.